Fig. 5From: Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective studyIgG sRBD ratio of V4 to V3 of symptomatic and asymptomatic haemodialysis patientsBack to article page